Glioblastoma in natalizumab‐treated multiple sclerosis patients

We present two natalizumab‐treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)‐wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Clin Transl Neurol
Autors principals: Sierra Morales, Fabian, Wright, Robert B., Novo, Jorge E., Arvanitis, Leonidas D., Stefoski, Dusan, Koralnik, Igor J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Brief Communications
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5497532/
https://ncbi.nlm.nih.gov/pubmed/28695151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.428
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars